Trump Advances Peptide Access Despite Concerns

The administration of U.S. President Donald Trump is working on developing plans to temporarily allow the sale of some peptides that were previously restricted, in order to enable pharmacies to produce certain types of them, despite not undergoing full safety testing. These peptides, which are often marketed for treatments such as weight loss, wound healing, and anti-aging, operate in an unregulated market that is rapidly growing, despite the ambiguity of their clinical evidence and the difficulty in monitoring them by health authorities. The plans include studying the approval of seven different types of peptides for various treatments, while experts express concerns about their safety and effectiveness, emphasizing that current evidence is insufficient for official marketing.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل